

# A preliminary safety and efficacy evaluation of direct delivery of autologous bone marrow-derived cells in Egyptian patients with type 1 diabetes mellitus

<b>Submission date</b> 30/03/2017	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 02/05/2017	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 02/05/2017	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Type 1 diabetes is a lifelong condition where the pancreas is unable to produce insulin, causing a person to have high or uncontrolled levels of blood sugar in their blood. It is a complex disease resulting from the autoimmune destruction of the majority of islet  $\beta$ -cells and requires patients to inject themselves with insulin to control their blood sugar. It is a major cause of morbidity (diseases) and mortality (death) worldwide. There is an option for stem cells to treat patients who are insulin dependent due to diabetes. Bone marrow is a diverse source of stem cells and transplantation could help repair and regenerate tissue that has been damaged. The normal way to deliver the stem cells (through injections into the arteries) has many problems. There is a possibility that taking stem cells from bone marrow and injecting it back into the person's pancreas could be feasible. The aim of this study is to evaluate the safety of a new strategy (designed to enhance the localization of where cells are injected to the diseased pancreas) by a single administration of autologous bone marrow derived mononuclear cells (A-BMMNCs) (that have certain types of stem cells) using a computed tomography (CT) scan-guided direct delivery route and to explore whether this treatment leads to improved  $\beta$ -cell function in diabetes patients.

### Who can participate?

Males and females aged two to 30 years old with confirmed Type 1 diabetes.

### What does the study involve?

Participants undergo a clinical examination and provide blood samples. They then undergo a bone marrow transplant done using a new strategy that uses a single administration of stem cells from bone marrow to a certain part of the pancreas (directly to the tail, not to the blood vessels that supply the pancreas). This is guided by a CT scanning machine. Participants are followed up for one year to see if there was any improvement or decrease in their  $\beta$ -cell function and diabetes symptoms.

What are the possible benefits and risks of participating?

Participants may benefit from being able to decrease or stop injecting insulin and having less diabetes complications. There is a risk of acute pancreatitis.

Where is the study run from?

Wadi EL-Neel Hospital (JCI) (Egypt)

When is the study starting and how long is it expected to run for?

January 2014 to June 2015

Who is funding the study?

Wadi EL-Neel Hospital (JCI) (Egypt)

Who is the main contact?

Professor Hazem Khamis

## Contact information

### Type(s)

Scientific

### Contact name

Prof Hazem Khamis

### Contact details

Wadi El-neel Hospital (JCI Accredited hospital)

Kobri Elkobba

Cairo

Egypt

19303

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

0000006555

## Study information

### Scientific Title

A preliminary safety and efficacy evaluation of direct intrapancreatic tail delivery of autologous bone marrow-derived cells in Egyptian patients with type 1 diabetes mellitus

### Study objectives

The aim of this study is to evaluate the safety of a new strategy (designed to enhance localization of the injected cells to the diseased pancreas along with avoidance of nonspecific organ entrapment) by a single administration of autologous bone marrow derived mononuclear cells (A-BMMNCs) via a computed tomography (CT) scan-guided direct transgastric intrapancreatic (DTI) delivery route and to explore whether this treatment leads to improved  $\beta$ -cell function in insulin dependent diabetes mellitus (IDDM) patients.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Wadi El-neel Ethical Committee, 13/01/2014, ref: 0000006555

### **Study design**

Prospective single centre interventional non randomised study

### **Primary study design**

Interventional

### **Secondary study design**

Non randomised study

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet'

### **Health condition(s) or problem(s) studied**

Type 1 diabetes mellitus

### **Interventions**

At baseline, participants undergo a clinical examinations and provide blood samples to assess for HbA1c, fasting C-peptide (FCP) and 2hour-C-peptide (2h-CP) levels (as indirect measures of endogenous insulin secretion), levels of islet cells and insulin antibodies. Insulin doses for each participant are determined.

Participants then undergo an autologous bone marrow transplant derived mononuclear cells. This is done using a new strategy (designed to enhance localisation of the injected cells to the diseased pancreas along with the avoidance of nonspecific organ entrapment) by a single administration of bone marrow-derived mononuclear cells (BM-MNCs) via a computed tomography (CT) scan-guided direct transgastric intrapancreatic (DTI) delivery route.

During the procedure, participants are assessed for bleeding from the bone marrow aspiration and transgastric puncture sites, abdominal pain and other clinical complaints (i.e. nausea, vomiting, pain and fever). Blood amylase levels are measured to exclude acute pancreatitis complications. Haematocrit values are obtained only in suspected bleed cases.

Participants are followed up between month one-two, three-five, six-eight, and after eight months (around 12 months) for any clinical complaints. After six months, if islet cells and insulin antibodies are abnormal and serologically positive before the transplantation, there are re-measured to record any improvement or decline in these antibodies. If the patients are negative for islet cell or insulin antibodies before the transplantation, the test is not repeated after six months (as it is not recommended as routine clinical practice). Participants are also followed up to measure their HbA1c, FCP, 2h-CP, insulin doses levels as well as their frequency of hospitalisation for hypo- and hyper-glycemic attacks (common acute short-term complications of uncontrolled diabetes that can lead to hospitalization and account for the majority of costs associated with diabetes care). Participants are encouraged to self-monitor blood glucose at least twice a day.

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Insulin, autologous bone marrow derived mononuclear cells

### **Primary outcome measure**

Safety is measured using the morbidity, mortality, and unwanted side effects (through patient records) during the procedure and at 12 month follow up.

### **Secondary outcome measures**

1. Serological changes in positive islet cell and insulin antibody levels are measured using blood samples at baseline and six months
2.  $\beta$ -cell function is measured using blood samples( HbA1c and in FCP and 2h-CP levels) at baseline, month one-two, month three-five, month six-eight and months eight to 12
3. Abdominal pain and other clinical parameters are measured using clinical examination during the procedure and at month one-two, month three-five, month six-eight and month 12

### **Overall study start date**

13/01/2014

### **Completion date**

13/06/2015

## **Eligibility**

### **Key inclusion criteria**

1. Males and females aged between 2 to 30 years of age
2. Confirmed T1D based on the American Diabetes association (ADA) 2015 criteria for diagnosis
3. Body mass index (BMI) of  $\leq 29.9$

**Participant type(s)**

Patient

**Age group**

Mixed

**Sex**

Both

**Target number of participants**

as large sample size as we can

**Key exclusion criteria**

1. Active infections
2. Any chronic or acute illness
3. Antibodies to hepatitis B surface antigen
4. Hepatitis C
5. Human immunodeficiency virus or evidence of diabetic complications at baseline
6. Pregnant, are breast-feeding or intend to become pregnant during the study
7. Clinically relevant uncontrolled medical conditions not associated with diabetes (such as hematologic, renal, hepatic, neurologic, cardiac and respiratory conditions)
8. Evidence of active malignancy or a prior history of active malignancy

**Date of first enrolment**

13/02/2014

**Date of final enrolment**

13/04/2014

**Locations****Countries of recruitment**

Egypt

**Study participating centre**

Wadi El-neel (JCI Accredited Hospital)

Kobri Elkobba

Cairo

Egypt

19303

**Sponsor information****Organisation**

Wadi EL-Neel hospital (JCI)

**Sponsor details**

Kobry Elkobba  
Cairo  
Egypt  
19303

**Sponsor type**

Hospital/treatment centre

**Funder(s)****Funder type**

Hospital/treatment centre

**Funder Name**

Wadi EL-Neel Hospital (JCI)

**Results and Publications****Publication and dissemination plan**

Planned publication in a peer reviewed high-impact journal.

**Intention to publish date**

31/05/2017

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are/will be available upon request from Raghda Moustafa Shahin at [Raghda.shahin@fop.usc.edu.eg](mailto:Raghda.shahin@fop.usc.edu.eg)

**IPD sharing plan summary**

Available on request